Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of
ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to
severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one
or more anti- tumor necrosis factor alpha (TNFα) therapies.